NO129771B - - Google Patents

Download PDF

Info

Publication number
NO129771B
NO129771B NO01020/71A NO102071A NO129771B NO 129771 B NO129771 B NO 129771B NO 01020/71 A NO01020/71 A NO 01020/71A NO 102071 A NO102071 A NO 102071A NO 129771 B NO129771 B NO 129771B
Authority
NO
Norway
Prior art keywords
water
emulsion
ointment
parts
film
Prior art date
Application number
NO01020/71A
Other languages
Norwegian (no)
Inventor
H Posphischil
Original Assignee
Vp Variopharm Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vp Variopharm Gmbh filed Critical Vp Variopharm Gmbh
Publication of NO129771B publication Critical patent/NO129771B/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007Drug-containing films, membranes or sheets
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S602/00Surgery: splint, brace, or bandage
    • Y10S602/904Film-forming bandage material

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
  • Cosmetics (AREA)

Description

Fremgangsmåte ved fremstilling av bruksferdig Procedure for the production of ready-to-use

" salvefolie. " ointment foil.

Foreliggende oppfinnelse angår en fremgangsmåte av den art som er angitt i krav l's ingress. The present invention relates to a method of the kind stated in claim 1's preamble.

Ved dermatologisk behandling av hudoverflater såvel som ved sårbehandling har salver vært anvendt i lang tid. Salver blir i alminnelighet påfort den huddel som skal behandles eller også, In dermatological treatment of skin surfaces as well as in wound treatment, ointments have been used for a long time. Ointments are generally applied to the skin area to be treated or,

som i tilfelle ved sårbehandling, påfort en salveklut, f.eks. gas, som legges over det sted som skal behandles. For å lette behand-lingen blir gasstrimler behandlet med salve, og fremstilles for eksempel i form av salvekompresser. Slike fremgangsmåter er anvendbare kun for vannfrie salver, som vaselin, vannfri eller nesten vannfri polyethylenglycol, mens emulsjonssaIver, spesielt av typen olje-i-vann, i form av bruksferdig salvegas, er utsatt for rask ut-torkning. De idag ikke lenger vanlige salveplastere var uhåndter- as in the case of wound treatment, apply an ointment cloth, e.g. gas, which is placed over the place to be treated. To facilitate treatment, gas strips are treated with ointment, and are produced, for example, in the form of ointment compresses. Such methods are applicable only for anhydrous ointments, such as vaseline, anhydrous or almost anhydrous polyethylene glycol, while emulsion ointments, especially of the oil-in-water type, in the form of ready-to-use ointment gas, are subject to rapid drying out. The ointment plasters, which are no longer common today, were unwieldy

lige i bruk. De inneholdt hefteplastiske voks- og fettmasser som måtte oppvarmes for påforing. Anvendelse av et pudder er, selvom det er lett påforbart ved stroing, ikke i alle tilfelle hensiktsmessig, fordi den store indre overflate opptar megen fuktighet, hvilket ikke alltid er onskelig. just in use. They contained sticky plastic wax and fat masses that had to be heated for application. The use of a powder is, although it is easily applied when ironing, not always appropriate, because the large inner surface absorbs a lot of moisture, which is not always desirable.

Fremgangsmåten ifolge oppfinnelsen er særpreget ved som som er angitt i kravets karakteriserende del. Salvefolien som fremstilles ifolge fremgangsmåten består av en vannfattig emulsjon av typen olje-i-vann, og er sammensatt av: a) 20 - 60 % av en fettfase av forskjellig sammensetning, som fettalkohol, vaselin, ullfett eller lignende, The method according to the invention is characterized by what is stated in the characterizing part of the claim. The ointment foil produced according to the method consists of a water-poor emulsion of the oil-in-water type, and is composed of: a) 20 - 60% of a fat phase of different composition, such as fatty alcohol, vaseline, wool grease or the like,

b) 2 - 12 % av et emulgeringsmiddel, b) 2 - 12% of an emulsifier,

c) 3 - 20 % av en filmdanner, c) 3 - 20% of a film former,

d) IO - 40 % av et fuktighetsbevarende middel, som glycerol, sorbitol, sukker eller lignende, og e) 1 - 15 % av et terapeutisk og/eller kosmetisk aktivt middel, samt d) 10 - 40% of a humectant, such as glycerol, sorbitol, sugar or similar, and e) 1 - 15% of a therapeutic and/or cosmetically active agent, as well as

1 - 15 % vann. 1 - 15% water.

Folien kan inneholde tilsetningsmid ler som forbedrer sal-vens dekkevne, eksempelvis titandioxyd, sinkoxyd og lignende. Som emulgeringsmiddel kommer i forste rekke ikke-ioniske, anionaktive eller kationaktive forbindelser i betraktning. Filmdanneren består av methyl- eller carboxymethylcellulose, eller et annet vannopplo-selig og svellbart cellulosederivat, alginat eller lignende. The foil can contain additives that improve the covering power of the ointment, for example titanium dioxide, zinc oxide and the like. Non-ionic, anion-active or cation-active compounds are primarily considered as emulsifiers. The film former consists of methyl or carboxymethyl cellulose, or another water-soluble and swellable cellulose derivative, alginate or the like.

Salvefolien fremstilles på basis av en emulsjonssalve av typen olje-i-vann. Salven blir derved bragt i en slik form at den raskt kan anvendes, og slik at man unngår å berore det sted som skal behandles, særlig sår. Ytterligere unngår man den unodvendige omvei å bestryke en gas med salve. Derved unngåes den sterke ut-torkningstendens som oppstår ved anvendelse av pudder, og gjor anvendelse som virkestoffbærer mere universell. Det har vist seg ved anvendelse av fremgangsmåten for fremstilling av bruksferdige dannede salvefolier at alle disse krav kan fylles. The ointment foil is produced on the basis of an emulsion ointment of the oil-in-water type. The ointment is thereby brought into such a form that it can be used quickly, and so that one avoids touching the place to be treated, especially wounds. Furthermore, the unnecessary detour of coating a gas with ointment is avoided. This avoids the strong drying tendency that occurs when using powder, and makes use as an active ingredient carrier more universal. It has been shown by using the method for producing ready-to-use formed ointment foils that all these requirements can be met.

Der er gjort forsok på å konservere olje-i-vann-emulsjoner ved vannuttrekning ved hjelp av torkeforstovning henholdsvis fryse-tdrkning. Efter tilsetning av vann lar slike konsentrater seg igjen tilbakefore til olje-i-vann-emulsjon ved mekanisk bearbeidel-se, som roring. Attempts have been made to preserve oil-in-water emulsions by water extraction using dry evaporation or freeze-drying. After the addition of water, such concentrates can be returned to an oil-in-water emulsion by mechanical processing, such as stirring.

Det har overraskende vist seg at en ytterligere vannuttrekning ved hjelp av varmede flater, som en varmevalse, samtidig gir, ved egnede olje-i-vann-emulsjoner, kompakte salver i folieform som på ideell måte tilfredsstiller alle fordringer. Salvefolien kan legges direkte på den del som skal behandles, og foyer seg efter den påforte kroppsdel. Alle påforingsvanskeligheter omgåes, og anvendelsen kan gjores meget mere hygienisk enn det som er mulig ved kjent salveterapi. Dette er spesielt interessant som folge av en rask påfbring ved lesjoner på store flater, ved forbrenning og i forbindelse med kirurgiske inngrep. Salvefolier fremstillet ifolge foreliggende oppfinnelse utviser en fremragende stabilitet og kan fremstilles sterilt i hygieniske éngangsforpakninger, hvilket er en fordel som ikke utvises av kjente olje-i-vann-emulsjoner i normale tubeforpakninger. It has surprisingly been shown that a further extraction of water by means of heated surfaces, such as a heating roller, at the same time produces, with suitable oil-in-water emulsions, compact ointments in foil form which ideally satisfy all requirements. The ointment foil can be placed directly on the part to be treated, and foir itself after the applied body part. All application difficulties are avoided, and the application can be made much more hygienic than is possible with known ointment therapy. This is particularly interesting as a result of a rapid application for lesions on large surfaces, for burns and in connection with surgical interventions. Ointment foils produced in accordance with the present invention exhibit excellent stability and can be manufactured sterile in hygienic disposable packaging, which is an advantage not shown by known oil-in-water emulsions in normal tube packaging.

Utgangsmaterialene som anvendes ved den oppfinneriske The starting materials used by the inventor

fremgangsmåte er kjente olje-i-vann-emulsjoner, altså emulsjoner av-ledet av en fettfase, f.eks. mineralolje, ozokerit, vaselin, paraf-fin, fettalkoholer, planteoljer, også i hydrert form, fettsyreeste-re og lignende. Ytterligere inneholder de et emulgeringsmiddel, eksempelvis natriumcetostearylsulfat, ethoxylerte fettalkoholer eller kompleksemulgeringsmidler, som polyoxyethylenderivater av sor-bitolanhydrider, eller også såpe eller andre kationiske forbindelser. Emulsjonens vannfase inneholder et fuktighetsbevarende middel, slik som sorbitol, glycerol, sukker, polyethylenglycol eller 1,2-propylenglycol. En slik utgangsemulsjon kan inneholde kjente virkestoffer, eksempelvis desinfiserende forbindelser som p-klor-m-kresol, oxykinolin, antibiotica, sulfonamid, hexaklorofen, acridin-farvestoffer, p-hydroxybenzoesyreestere, men også desinfeksjonsmid-ler av kationisk type, som f.eks. benzalkoniumklorid, cetylpyridin-iumklorid osv. Ytterligere anvendbare virkestoffer er garvestoffer, allantoin, urea, azulen, planteekstrakter, cortisonderivater, vita-miner, hormoner osv. Hovedsakelig er alle kjente virkestoffer som kan anvendes i blje-i-vann-emulsjoner også anvendbare i salvefolier. method are known oil-in-water emulsions, i.e. emulsions derived from a fat phase, e.g. mineral oil, ozokerite, vaseline, paraffin, fatty alcohols, vegetable oils, also in hydrated form, fatty acid esters and the like. Furthermore, they contain an emulsifier, for example sodium cetostearyl sulphate, ethoxylated fatty alcohols or complex emulsifiers, such as polyoxyethylene derivatives of sorbitol anhydrides, or also soap or other cationic compounds. The water phase of the emulsion contains a humectant, such as sorbitol, glycerol, sugar, polyethylene glycol or 1,2-propylene glycol. Such a starting emulsion can contain known active substances, for example disinfectant compounds such as p-chloro-m-cresol, oxyquinoline, antibiotics, sulfonamide, hexachlorophene, acridine dyes, p-hydroxybenzoic acid esters, but also disinfectants of the cationic type, such as e.g. benzalkonium chloride, cetylpyridinium chloride, etc. Further usable active substances are tanning substances, allantoin, urea, azulene, plant extracts, cortisone derivatives, vitamins, hormones, etc. Mainly all known active substances that can be used in diaper-in-water emulsions are also usable in ointment foils .

Disse emulsjoner tilsettes én eller flere filmdannende forbindelser. Av dem som er egnede er eksempelvis carboxyvinylpo-lymerer, methylcellulose, carboxymethyleellulose og andre vannopploselige cellulosederivater, vegetabilske slimdannere, alginat, polyvinylpyrrolidon, copolymerisat av polyvinylpyrrolidon ig vinyl-acetat, agaragar, carragen eller "Dextran" osv. Emulsjonens konsistens innstilles med vann eller vann-alkoholblanding til en rela-tivt lettflytende pasta. Den erholdte pasta utstrykes ved hjelp av valsing eller bestrykning på et underlag, som metallplate, glass eller lignende, og ved oppvarmning av underlaget avdampes vannfasen til en restfuktighet på 1 - 15 %. Spesielt egnet for torkeprosessen er også varmede valser. For lettere å kunne fjerne den derved dannede film er det hensiktsmessig å belegge metallpla-ten eller valsen med et egnet kunststoff, f.eks. polyethylen eller polytetrafluorethylen, emalje eller glasur. Torketemperaturen er i området 65 - 110°C. Ved anvendelse av omfindtlige virkestoffer kan vakuum fordelaktig benyttes. Pådraget av pasta skal innstilles slik at efter torkeprosessen erholdes der en film med den onskede fi lmtykkeIse. One or more film-forming compounds are added to these emulsions. Among those that are suitable are, for example, carboxyvinyl polymers, methylcellulose, carboxymethylcellulose and other water-soluble cellulose derivatives, vegetable slime formers, alginate, polyvinylpyrrolidone, copolymer of polyvinylpyrrolidone and vinyl acetate, agar agar, carrageenan or "Dextran", etc. The consistency of the emulsion is adjusted with water or water -alcohol mixture into a relatively easy-flowing paste. The obtained paste is spread by means of rolling or coating on a substrate, such as metal plate, glass or the like, and when the substrate is heated, the water phase evaporates to a residual moisture of 1 - 15%. Heated rollers are also particularly suitable for the drying process. In order to be able to remove the resulting film more easily, it is appropriate to coat the metal plate or the roller with a suitable synthetic material, e.g. polyethylene or polytetrafluoroethylene, enamel or glaze. The drying temperature is in the range 65 - 110°C. When using bulky active substances, vacuum can be advantageously used. The application of paste must be set so that after the drying process a film with the desired film thickness is obtained.

Ved en annen utforelsesform fremstilles en emulsjon som tidligere angitt, som en tykk pasta, som derefter omdannes til en deigkonsistens i en vakuumkjele under anvendelse av varme. Deane masse utvalses til tynne folier som i henhold til den forste utforelsesform eftertdrkes på varmede plater eller valser for derved å innstille det endelige vanninnhold på det onskede nivå. In another embodiment, an emulsion is prepared as previously indicated, as a thick paste, which is then converted to a dough consistency in a vacuum boiler using heat. The resulting mass is rolled out into thin foils which, according to the first embodiment, are pressed onto heated plates or rollers to thereby set the final water content at the desired level.

Hensiktsmessig filmtykkelse er i området 0,2 - 1.5 mm. En således fremstillet kompakt salve i folieform er påforbar og flek-sibel. Når denne film påfores den hudflate som skal behandles, ligger den i nær flatekontakt med underlaget. Derved kan fuktighet uttrekkes, spesielt ved væskende eksem eller blodende sår. Angiv-else av virkestoff på overflatekontaktstedet er derved fullstendig sikret. En salvefilm fremstillet efter denne fremgangsmåte kan anvendes i sin opprinnelige form, men den kan også påvalses ensidig på et gassubstrat. Spesielt egnet er disse salvefilmer som salve-underlag ved heftplastre, eventuelt i stedet for gaspolstringen. Ved en mekanisk forbindelse mellom salvefilmene og gas kan brann-sårbandasjer fremstilles. I stedet for gas kan også andre vevnader anvendes. Salvefolien fremstillet ifolge oppfinnelsen er en vannfattig olje-i-vann-emulsjon, men som allikevel utviser en ekte emulsjons egenskaper. Den er dispergerbar i vann og danner en fly-tende emulsjon. En ytterligere inntbrkning forhindres av det an-vendte fuktighetsbevarende middel. Ytterligere kan salvefolien, inntil bruk, forsegles i et vannugjennomtrengelig materiale. Appropriate film thickness is in the range 0.2 - 1.5 mm. A thus produced compact ointment in foil form is easy to apply and flexible. When this film is applied to the skin surface to be treated, it is in close surface contact with the substrate. Thereby, moisture can be extracted, especially in the case of oozing eczema or bleeding wounds. Indication of active substance at the surface contact point is thereby completely ensured. An ointment film produced according to this method can be used in its original form, but it can also be rolled on one side on a gas substrate. These ointment films are particularly suitable as an ointment substrate for adhesive plasters, possibly instead of the gas padding. By a mechanical connection between the ointment films and gas, burn wound dressings can be produced. Instead of gas, other tissues can also be used. The ointment foil produced according to the invention is a water-poor oil-in-water emulsion, but which nevertheless exhibits the properties of a real emulsion. It is dispersible in water and forms a flowable emulsion. Further absorption is prevented by the humectant used. Furthermore, the ointment foil can be sealed in a water-impermeable material until use.

Eksempler Examples

1.) Til fremstilling av en ikke-ionisk emulsjon ble fettfasen 1.) To produce a non-ionic emulsion, the fat phase was

bestående av 3 deler vaselin, 5 deler cetostearylalkohol og 1 del fet talkoholpolyglycolether med et hydroxyltall på 80-120 consisting of 3 parts vaseline, 5 parts cetostearyl alcohol and 1 part fatty tall alcohol polyglycol ether with a hydroxyl number of 80-120

sammensmeltet. Vannfasen som besto av 2 deler lavviskos méthylcel-lulose, 1 del polyvinylpyrrolidon, 6 deler glycerol, 1 del panthe-nol, 1 del allantoin, 0,1 del benzalkoniumklorid og 80 deler vann, ble oppvarmet til ca. 70°C. Derefter ble på kjent måte vannfasen og fettfasen emulgert. Den ferdige emulsjon ble revet med 3 deler sinkoxyd. Den erholdte masse ble utstroket i en tykkelse på ca. 2 mm på en "teflon"-bestroket metallplate hvorefter vannet ble inndampet ved 100°C til en restfuktighet på ca. 3 - 4 % i filmen. Den erholdte film ble avtatt og var bruksferdig. 2. ) For fremstilling av en anionaktiv emulsjon ble fettfasen bestående av 0,2 deler paraffinolje, 3 deler ozokerit, 3 deler vaselin og 5 deler cetylstearylalkohol (DAB^) (3.tillegg), sammensmeltet. Vannfasen bestående av 2,5 deler carboxymethylcellulose, 7 deler sorbitol, 0,1 del natrium-p-klor-m-kreosolat og 90 deler vann ble oppvarmet til ca. 70°C. Vannfasen og fettfasen ble emulgert på kjent måte, og den ferdige emulsjon ble påfort en oppvarmet, langsomt roterende valse i et lag på 2 mm tykkelse, og vannet ble avdampet til en restfuktighet på ca. 5 %. 3. ) For fremstilling av en ikke-ionisk emulsjon ble en fettfa se bestående av 6 deler vaselin, 10 deler cetylstearylalkohol, 1 del stearinsyre og 2 deler polyoxyethylensorbitolmonooleat, smeltet. Vannfasen bestående av 4 deler methylcellulose, 10 deler glycerin, 1 del allantoin og 80 deler vann oppvarmet til ca. 70°C. Vannfasen og fettfasen ble emulgert på kjent måte. I den ferdige emulsjon ble 0,5 deler "Neomycinsulfat" og 0,05 deler vitamin E-acetat innarbeidet. Derefter ble emulsjonen utstroket på en plate i et 3 mm tykt lag og derefter torket i vakuum ved ca. 50°C. Restfuk-tigheten i den erholdte film var 5 %. 4. ) En anionaktiv emulsjon ble fremstillet av en vannfase be stående av 3,3 deler vaselin, 6,4 deler emulgerende cetylstearylalkohol (DAB^(3.tillegg)), 0,5 deler polyethylenglycol-400-stearat, 0,1 del p-hydroxybenzoesyrebutylester, 0,2 deler "Adeps lanae" som ble sammensmeltet. Vannfasen bestående av 2,2 deler carboxymethylcellulose, 1,2 deler polyvinylpyrrolidon, 5 deler "Polyethylenglycol 4O0", 3 deler urea og 60 deler vann ble oppvarmet til ca. 70°C. Vannfasen og fettfasen ble emulgert på kjent måte, hvorefter den erholdte masse ble inndampet i en vakuumkjele under om-roring inntil en deigaktig konsistens ble erholdt. Denne pastalig-nende masse ble utvalset tynt på en metallplate og derefter torket ved 100°C inntil en restfuktighet på ca. 5 %. 5.) Emulsjonen ifolge eksempel 1 ble utstroket på en metall plate i et ca. 3 mm tykt lag. For fordelingen på metall-platen blir et lag gas innlemret i massen. Derefter fjernes vannet ved avdampning ved ca. 100°C til en restfuktighet på ca. 3 - 4 %. merged. The water phase, which consisted of 2 parts low-viscosity methyl cellulose, 1 part polyvinylpyrrolidone, 6 parts glycerol, 1 part panthenol, 1 part allantoin, 0.1 part benzalkonium chloride and 80 parts water, was heated to approx. 70°C. The water phase and the fat phase were then emulsified in a known manner. The finished emulsion was torn with 3 parts zinc oxide. The mass obtained was spread out to a thickness of approx. 2 mm on a Teflon-coated metal plate, after which the water was evaporated at 100°C to a residual moisture of approx. 3 - 4% in the film. The obtained film was taken down and was ready for use. 2. ) For the production of an anionic emulsion, the fat phase was consisting of 0.2 parts of paraffin oil, 3 parts of ozokerite, 3 parts of vaseline and 5 parts of cetyl stearyl alcohol (DAB^) (3rd addition), fused. The water phase consisting of 2.5 parts carboxymethylcellulose, 7 parts sorbitol, 0.1 part sodium p-chloro-m-creosolate and 90 parts water was heated to approx. 70°C. The water phase and the fat phase were emulsified in a known manner, and the finished emulsion was applied to a heated, slowly rotating roller in a layer of 2 mm thickness, and the water was evaporated to a residual moisture of approx. 5%. 3. ) For the preparation of a non-ionic emulsion, a fat fa see consisting of 6 parts vaseline, 10 parts cetyl stearyl alcohol, 1 part stearic acid and 2 parts polyoxyethylene sorbitol monooleate, melted. The water phase consisting of 4 parts methylcellulose, 10 parts glycerin, 1 part allantoin and 80 parts water heated to approx. 70°C. The water phase and the fat phase were emulsified in a known manner. In the finished emulsion, 0.5 parts of "Neomycin sulfate" and 0.05 parts of vitamin E acetate were incorporated. The emulsion was then spread on a plate in a 3 mm thick layer and then dried in vacuum at approx. 50°C. The residual moisture in the obtained film was 5%. 4. ) An anionic emulsion was prepared from a water phase be consisting of 3.3 parts petroleum jelly, 6.4 parts emulsifying cetyl stearyl alcohol (DAB^(3rd addition)), 0.5 parts polyethylene glycol-400 stearate, 0.1 part p-hydroxybenzoic acid butyl ester, 0.2 parts "Adeps lanae" which were merged. The water phase consisting of 2.2 parts carboxymethylcellulose, 1.2 parts polyvinylpyrrolidone, 5 parts "Polyethyleneglycol 4O0", 3 parts urea and 60 parts water was heated to approx. 70°C. The water phase and the fat phase were emulsified in a known manner, after which the obtained mass was evaporated in a vacuum boiler with stirring until a pasty consistency was obtained. This paste-like mass was rolled out thinly on a metal plate and then dried at 100°C until a residual moisture of approx. 5%. 5.) The emulsion according to example 1 was spread on a metal plate in an approx. 3 mm thick layer. For distribution on the metal plate, a layer of gas is incorporated into the mass. The water is then removed by evaporation at approx. 100°C to a residual moisture of approx. 3 - 4%.

Claims (5)

1. Fremgangsmåte ved fremstilling av salvefolie i bruksferdig formet tilstand, spesielt for dermatologisk behandling av hudflater,karakterisert vedat der på i og for seg kjent måte fremstilles en olje-i-vann emulsjon inneholdende: a) 20-60 vektdeler av en fettfase såsom fettalkohol, vaselin, ullfett og lignende, b) 2-12 " emulgeringsmiddel, c) 3 - 20 " filmdannende middel, d) 10 - 40 " fuktighetsbevarende middel, såsom glycerol, sorbiton, sukker, og lignende, e) 1-15 " terapeutisk og/eller kosmetisk virkestoff, hvorefter emulsjonen utstrykes på et underlag og varmebehandles inntil vanninnholdet blir 1 - 15 %.1. Procedure for the production of ointment foil in a ready-to-use form, especially for dermatological treatment of skin surfaces, characterized in that an oil-in-water emulsion containing: a) 20-60 parts by weight of a fatty phase such as fatty alcohol is produced in a manner known per se , vaseline, wool grease and the like, b) 2-12 " emulsifying agent, c) 3-20 " film-forming agent, d) 10-40 " humectant, such as glycerol, sorbitol, sugar, and the like, e) 1-15 " therapeutic and/or cosmetic active ingredient, after which the emulsion is spread on a substrate and heat-treated until the water content is 1 - 15%. 2. Fremgangsmåte ifolge krav 1,karakterisert vedat emulsjonen ytterligere tilsettes titandioxyd, sinkoxyd eller lignende.2. Method according to claim 1, characterized in that titanium dioxide, zinc oxide or the like is further added to the emulsion. 3. Fremgangsmåte ifolge krav 1-2,karakterisert vedat der som filmdanner anvendes methyl-, carboxymethylcellulose eller andre vannopploselige eller svellende cellulosederivater eller et alginat.3. Method according to claims 1-2, characterized in that methyl, carboxymethyl cellulose or other water-soluble or swelling cellulose derivatives or an alginate are used as film formers. 4. Fremgangsmåte ifolge krav 1-3,karakterisert vedat ut-gangsemulsjonen fordeles eller bestrykes på plater eller tdrkevalser i egnede skikttykkelser, og at skikttykkelsen velges slik at efter en ytterligere fjernelse av vann erholdes en salvefilm med skikttyk-kelse på 0,2 - 2 mm.4. Method according to claims 1-3, characterized in that the starting emulsion is distributed or coated on plates or drying rollers in suitable layer thicknesses, and that the layer thickness is chosen so that after a further removal of water, an ointment film is obtained with a layer thickness of 0.2 - 2 etc. 5. Fremgangsmåte ifolge krav 1-4,karakterisert vedat vannet fjernes ved avdampning under anvendelse av varme, fortrinnsvis ved en temperatur på 65 - HO°C ved normalt trykk og derefter ved ca. 50°C under vakuum.5. Method according to claims 1-4, characterized in that the water is removed by evaporation using heat, preferably at a temperature of 65 - HO°C at normal pressure and then at approx. 50°C under vacuum.
NO01020/71A 1970-03-18 1971-03-17 NO129771B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE2012775A DE2012775C3 (en) 1970-03-18 1970-03-18 Ointment foils and process for their manufacture

Publications (1)

Publication Number Publication Date
NO129771B true NO129771B (en) 1974-05-27

Family

ID=5765402

Family Applications (1)

Application Number Title Priority Date Filing Date
NO01020/71A NO129771B (en) 1970-03-18 1971-03-17

Country Status (15)

Country Link
US (1) US3803300A (en)
AT (1) AT302530B (en)
BE (1) BE764422A (en)
CA (1) CA945897A (en)
CH (1) CH575758A5 (en)
DE (1) DE2012775C3 (en)
DK (1) DK131088B (en)
ES (1) ES388980A1 (en)
FR (1) FR2083366B1 (en)
GB (1) GB1320309A (en)
IE (1) IE35025B1 (en)
LU (1) LU62798A1 (en)
NL (1) NL7103560A (en)
NO (1) NO129771B (en)
SE (1) SE368508B (en)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2432925C3 (en) * 1974-07-05 1985-11-21 Schering AG, 1000 Berlin und 4709 Bergkamen Film-shaped medicinal products
AR207805A1 (en) * 1975-02-06 1976-10-29 Alza Corp SUITABLE SUBSTRATE TO FORM DRESSINGS FOR THE CONTINUOUS DISPENSATION OF BASE SCCOPOLAMINE BY TRANSDERMAL ROUTE
DE2517452C3 (en) * 1975-04-19 1978-11-02 Fa. Carl Freudenberg, 6940 Weinheim Collagen foil for cosmetic use
US4113854A (en) * 1977-01-10 1978-09-12 Minnesota Mining And Manufacturing Company Prophylactic treatment of mastitis
FR2405068A1 (en) * 1977-10-10 1979-05-04 Sauba Lab Water in oil emulsions for dry skin - contg. vitamin=A, stigmasterol, allantoin, and alpha tocopherol
US4291014A (en) * 1979-01-11 1981-09-22 Key Pharmaceuticals, Inc. Polymeric diffusion matrix containing estradiol diacetate
FR2455459A1 (en) * 1979-05-02 1980-11-28 Sertog Carboxy:methylcellulose matrix for slow release of volatile cpd. - contains tri:ethanolamine, stearin and an alcohol e.g. cetyl is esp. useful for perfumes, insect repellents eczema treatment etc.
US4291015A (en) * 1979-08-14 1981-09-22 Key Pharmaceuticals, Inc. Polymeric diffusion matrix containing a vasodilator
CA1163559A (en) * 1980-07-09 1984-03-13 Alec D. Keith Polymeric diffusion matrix for administration of drugs
US4357935A (en) * 1980-11-12 1982-11-09 C. R. Canfield & Company, Inc. Dry method of making a dry socket dressing
IL61721A (en) * 1980-12-16 1984-03-30 Blank Izhak Nitroglycerin preparations
US4591501A (en) * 1981-04-13 1986-05-27 Seton Company Cosmetic and pharmaceutical sheet material containing polypeptides
US4585797A (en) * 1981-04-13 1986-04-29 Seton Company Cosmetic and pharmaceutical sheet material containing polypeptides
US4482533A (en) * 1982-01-11 1984-11-13 Key Pharmaceuticals, Inc. Polymeric diffusion matrix containing propranolol
EP0139127A1 (en) * 1983-08-22 1985-05-02 F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft Transdermal drug delivery device and its preparation
FR2649318A1 (en) * 1989-07-07 1991-01-11 Tisnes Paul Dehydrated pharmaceutical dosage forms for dermatological and cosmetic use
EP0409383B1 (en) * 1989-07-21 1994-04-06 Izhak Blank Estradiol compositions and methods for topical applications
US5232703A (en) * 1989-07-21 1993-08-03 Izhak Blank Estradiol compositions and methods for topical application
GB9017800D0 (en) * 1990-08-14 1990-09-26 Unilever Plc Moisture barrier and its preparation
US6221403B1 (en) * 1992-08-08 2001-04-24 Seton Healthcare Group Plc Topical composition
GB2269745B (en) * 1992-08-08 1996-08-07 Seton Healthcare Group Plc A zinc oxide topical composition
DE4420625C1 (en) * 1994-06-14 1995-11-02 Beiersdorf Ag Active substance combination with a content of glycerylalkyl ethers and cosmetic and dermatological preparations containing such active substance combinations
US20030211136A1 (en) * 1998-09-25 2003-11-13 Neema Kulkarni Fast dissolving orally consumable films containing a sweetener
US6596298B2 (en) 1998-09-25 2003-07-22 Warner-Lambert Company Fast dissolving orally comsumable films
US20030206942A1 (en) * 1998-09-25 2003-11-06 Neema Kulkarni Fast dissolving orally consumable films containing an antitussive and a mucosa coating agent
US6245960B1 (en) 1999-05-13 2001-06-12 Board Of Trustees Of The University Of Arkansas Inherent healing accelerator
DE10034491A1 (en) * 2000-07-15 2002-01-24 Scs Skin Care Systems Gmbh Foil dermatics
US20040228892A1 (en) * 2003-02-28 2004-11-18 Berry Craig J. Delivery system for cosmetic and skincare products
US7666396B2 (en) * 2003-09-11 2010-02-23 Kimberly-Clark Worldwide, Inc. Single-use moisturizing product
US20070110792A9 (en) * 2005-01-03 2007-05-17 L'oreal Cosmetic or dermatological article comprising a medium that is soluble in water
FR2880262B1 (en) * 2005-01-03 2013-11-08 Oreal COSMETIC OR DERMATOLOGICAL ARTICLE COMPRISING A WATER-SOLUBLE SUPPORT
US20070259029A1 (en) * 2006-05-08 2007-11-08 Mcentire Edward Enns Water-dispersible patch containing an active agent for dermal delivery
US20070258935A1 (en) * 2006-05-08 2007-11-08 Mcentire Edward Enns Water dispersible films for delivery of active agents to the epidermis
US20080057090A1 (en) * 2006-09-01 2008-03-06 Mcentire Edward Enns Wrinkle masking film composition for skin
US7879942B2 (en) * 2006-10-05 2011-02-01 Eastman Chemical Company Switchable adhesive article for attachment to skin and method of using the same

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR851701A (en) * 1938-03-15 1940-01-13 Protective paste

Also Published As

Publication number Publication date
ES388980A1 (en) 1974-05-01
FR2083366A1 (en) 1971-12-17
DE2012775B2 (en) 1973-03-01
DE2012775C3 (en) 1973-10-04
US3803300A (en) 1974-04-09
DK131088B (en) 1975-05-26
LU62798A1 (en) 1971-08-23
IE35025L (en) 1971-09-18
DK131088C (en) 1975-10-27
GB1320309A (en) 1973-06-13
DE2012775A1 (en) 1971-09-30
NL7103560A (en) 1971-09-21
CH575758A5 (en) 1976-05-31
AT302530B (en) 1972-10-25
CA945897A (en) 1974-04-23
BE764422A (en) 1971-08-16
SE368508B (en) 1974-07-08
FR2083366B1 (en) 1974-05-31
IE35025B1 (en) 1975-10-15

Similar Documents

Publication Publication Date Title
NO129771B (en)
AU2001283909B2 (en) Solution-, Dispersion-or emulsion-producing film dermatics
DE2432925B2 (en) Film-shaped drugs or placebos
CA1067407A (en) Pharmaceutical preparation in the form of a foil having an active substance incorporated therein
US5456745A (en) Flexible, hydrophilic gel film, the process for its production and the use of it
US20040143026A1 (en) Bioadhesive hydrophilic composition for treatment of mammalian skin
HUT75288A (en) Hydrophilic, hot-melt-type pressure-sensitive adhesive
JPH05504895A (en) transdermal system
NO180618B (en) Process for the preparation of compositions which form in situ films on body tissue
DE2449865B2 (en) Film-shaped medicinal product
MXPA06003316A (en) Transdermal pharmaceutical formulation for minimizing skin residues.
US20100126650A1 (en) Process for producing preparation for oral administration
US2464755A (en) Coated gauze
NO124623B (en)
EP1711160A2 (en) Flat system for using in the oral cavity
NL8302492A (en) CROSSES POLY BETA-ALANINE AND ITS DIFFERENT APPLICATIONS.
JPH05194180A (en) Sheet-formed pack cosmetic
DE19712699C2 (en) Process for the production of wound dressings with wound care active substances
RU2295956C2 (en) Potentiated compositions for topical using
TWI776879B (en) body makeup
Kishchenko et al. Films in Russian medicine and cosmetology: development history, classification, technology
WO2021002124A1 (en) Moisturizing film cosmetic material
Vakhariya et al. Preparation of novel biocompatible honey hydrogel with turmaric and Aloe vera.
JPH0436133B2 (en)
Tarasenko et al. Features of the development of soft dosage forms